VIM and colorectal carcinoma: As seventy percent of metastatic CRC samples were positive for phosphorylated vimentin, peptide-reactive CD4 T-cells recognized phosphorylated vimentin-positive tumor cells directly or indirectly, and phosphorylated vimentin could become a helper peptide vaccine to treat CRC [17].